vigabatrin has been researched along with Disease Models, Animal in 69 studies
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The goal of our study was to examine the long-term effect of vigabatrin (VGB), a γ-aminobutyric acid aminotransferase (GABA-AT) inhibitor on clonazepam (CLO), ethosuximide (ETX) and valproate (VPA) anticonvulsive activity against pentylenetetrazole (PTZ)-induced seizures in mice." | 7.96 | Long-term vigabatrin treatment modifies pentylenetetrazole-induced seizures in mice: focused on GABA brain concentration. ( Czuczwar, SJ; Krzyżanowski, M; Świąder, K; Świąder, MJ; Wróbel, A; Zakrocka, I; Łuszczki, JJ, 2020) |
| " While seizures are usually intractable to medication in tuberous sclerosis complex (TSC), a common genetic cause of epilepsy, vigabatrin appears to have unique efficacy for epilepsy in TSC." | 7.79 | Vigabatrin inhibits seizures and mTOR pathway activation in a mouse model of tuberous sclerosis complex. ( McDaniel, SS; Rensing, NR; Wong, M; Zhang, B, 2013) |
| " The Food and Drug Administration-approved anti-epileptic vigabatrin has prevented HBO-induced seizures in rats up to 132 fsw." | 7.79 | Vigabatrin prevents seizure in swine subjected to hyperbaric hyperoxia. ( Bodo, M; Hall, AA; Mahon, RT; Young, C, 2013) |
| "To characterize the type of interactions between vigabatrin (VGB) and tiagabine (TGB) -- two newer antiepileptic drugs influencing GABA-ergic neurotransmitter system, the isobolographic analysis was used in two experimental models of epilepsy: the maximal electroshock seizure threshold (MEST) test and pentylenetetrazole (PTZ)-induced seizures in mice." | 7.74 | Isobolographic characterization of interactions between vigabatrin and tiagabine in two experimental models of epilepsy. ( Czuczwar, SJ; Luszczki, JJ, 2007) |
| "The effect of systemic administration of the gamma-aminobutyric acid (GABA)-transaminase inhibitor vigabatrin (VGB) on different components of convulsions was tested in the model of audiogenically kindled seizures, which consist of brainstem (running, tonus) and forebrain (clonus) elements." | 7.73 | Vigabatrin in low doses selectively suppresses the clonic component of audiogenically kindled seizures in rats. ( Kuznetsova, GD; Shatskova, AB; van Rijn, CM; Vinogradova, LV, 2005) |
| "Vigabatrin is a rationally developed antiepileptic drug, which acts by increasing GABA levels in the brain by irreversibly inhibiting GABA degradation." | 5.38 | Vigabatrin for focal drug delivery in epilepsy: bilateral microinfusion into the subthalamic nucleus is more effective than intranigral or systemic administration in a rat seizure model. ( Backofen-Wehrhahn, B; Bankstahl, M; Bröer, S; Gernert, M; Gey, L; Löscher, W, 2012) |
| "Clonic seizures were rare in NMDA-treated P25 rats, but valproate pretreatment increased their incidence significantly." | 5.36 | Vigabatrin but not valproate prevents development of age-specific flexion seizures induced by N-methyl-D-aspartate (NMDA) in immature rats. ( Kubová, H; Mares, P, 2010) |
| "1995)." | 5.34 | Vigabatrin, a GABA transaminase inhibitor, reversibly eliminates tinnitus in an animal model. ( Bauer, CA; Brozoski, TJ; Spires, TJ, 2007) |
| "The goal of our study was to examine the long-term effect of vigabatrin (VGB), a γ-aminobutyric acid aminotransferase (GABA-AT) inhibitor on clonazepam (CLO), ethosuximide (ETX) and valproate (VPA) anticonvulsive activity against pentylenetetrazole (PTZ)-induced seizures in mice." | 3.96 | Long-term vigabatrin treatment modifies pentylenetetrazole-induced seizures in mice: focused on GABA brain concentration. ( Czuczwar, SJ; Krzyżanowski, M; Świąder, K; Świąder, MJ; Wróbel, A; Zakrocka, I; Łuszczki, JJ, 2020) |
| "Proline dehydrogenase (PRODH), which degrades L-proline, resides within the schizophrenia-linked 22q11." | 3.83 | Cytosolic Accumulation of L-Proline Disrupts GABA-Ergic Transmission through GAD Blockade. ( Crabtree, GW; Gogos, JA; Gordon, JA; Park, AJ, 2016) |
| "We recently reported that forward acoustic masking can enhance the auditory brainstem response (ABR) in rats treated with a high dose of sodium salicylate (NaSal), a tinnitus inducer, when tested in open acoustic field (Liu and Chen, 2012, Brain Research 1485, 88-94)." | 3.81 | Forward acoustic masking enhances the auditory brainstem response in a diotic, but not dichotic, paradigm in salicylate-induced tinnitus. ( Chen, L; Liu, XP, 2015) |
| " While seizures are usually intractable to medication in tuberous sclerosis complex (TSC), a common genetic cause of epilepsy, vigabatrin appears to have unique efficacy for epilepsy in TSC." | 3.79 | Vigabatrin inhibits seizures and mTOR pathway activation in a mouse model of tuberous sclerosis complex. ( McDaniel, SS; Rensing, NR; Wong, M; Zhang, B, 2013) |
| " The Food and Drug Administration-approved anti-epileptic vigabatrin has prevented HBO-induced seizures in rats up to 132 fsw." | 3.79 | Vigabatrin prevents seizure in swine subjected to hyperbaric hyperoxia. ( Bodo, M; Hall, AA; Mahon, RT; Young, C, 2013) |
| "To determine whether a new model of cryptogenic infantile spasms consisting of prenatal priming with betamethasone and postnatal trigger of spasms by N-methyl-D-aspartate (NMDA) responds to chronic adrenocorticotropic hormone (ACTH) treatment, and has electroencephalography (EEG) signature, efficacy of treatments, and behavioral impairments similar to those in human infantile spasms." | 3.77 | Validation of the rat model of cryptogenic infantile spasms. ( Chachua, T; Velíšek, L; Velíšková, J; Yum, MS, 2011) |
| "To characterize the interactions between levetiracetam and the antiepileptic drugs gabapentin, tiagabine, and vigabatrin in suppressing pentylenetetrazole-induced clonic seizures in mice, type II isobolographic analysis was used." | 3.75 | Pharmacodynamic and pharmacokinetic interaction profiles of levetiracetam in combination with gabapentin, tiagabine and vigabatrin in the mouse pentylenetetrazole-induced seizure model: an isobolographic analysis. ( Andres-Mach, MM; Czuczwar, SJ; Dudra-Jastrzebska, M; Luszczki, JJ; Patsalos, PN; Ratnaraj, N; Sielski, M, 2009) |
| " Isobolographic analysis was used in two mouse experimental models of epilepsy: the maximal electroshock seizure threshold test and pentylenetetrazole-induced seizures." | 3.74 | Isobolographic and behavioral characterizations of interactions between vigabatrin and gabapentin in two experimental models of epilepsy. ( Czuczwar, SJ; Luszczki, JJ; Patsalos, PN; Ratnaraj, N, 2008) |
| "To characterize the type of interactions between vigabatrin (VGB) and tiagabine (TGB) -- two newer antiepileptic drugs influencing GABA-ergic neurotransmitter system, the isobolographic analysis was used in two experimental models of epilepsy: the maximal electroshock seizure threshold (MEST) test and pentylenetetrazole (PTZ)-induced seizures in mice." | 3.74 | Isobolographic characterization of interactions between vigabatrin and tiagabine in two experimental models of epilepsy. ( Czuczwar, SJ; Luszczki, JJ, 2007) |
| "The effect of systemic administration of the gamma-aminobutyric acid (GABA)-transaminase inhibitor vigabatrin (VGB) on different components of convulsions was tested in the model of audiogenically kindled seizures, which consist of brainstem (running, tonus) and forebrain (clonus) elements." | 3.73 | Vigabatrin in low doses selectively suppresses the clonic component of audiogenically kindled seizures in rats. ( Kuznetsova, GD; Shatskova, AB; van Rijn, CM; Vinogradova, LV, 2005) |
| " The present studies extended that observation by examining the cardiovascular response to injection into the nucleus tractus solitarius of a selective GABAB receptor antagonist, CGP 35348, in these strains as well as examining the cardiovascular responses to stimulation or blockade of GABAB receptors in the nucleus tractus solitarius in another model of hypertension, the rat treated with deoxycorticosterone acetate and salt." | 3.68 | Enhanced gamma-aminobutyric acid-mediated responses in nucleus tractus solitarius of hypertensive rats. ( Sved, AF; Tsukamoto, K, 1993) |
| "Taurine levels were 67% lower in vigabatrin-treated animals than in control animals." | 2.74 | Taurine deficiency is a cause of vigabatrin-induced retinal phototoxicity. ( Chiron, C; Collins, SD; Coriat, C; Craft, CM; Duboc, A; Dubus, E; Dulac, O; Jammoul, F; Nabbout, R; Picaud, S; Sahel, JA; Simonutti, M; Wang, Q; Ye, W, 2009) |
| "Infantile spasms are the classical seizure type of West syndrome." | 2.46 | Modeling new therapies for infantile spasms. ( Betancourth, D; Chudomelova, L; Coppola, A; Galanopoulou, AS; Raffo, E; Scantlebury, MH, 2010) |
| "Vigabatrin (VGB) was designed specifically to inhibit GABA transaminase and thereby increase the availability of GABA in the brain." | 2.39 | Vigabatrin. ( Ben-Menachem, E, 1995) |
| " The data demonstrate that chronic administration of very low, nontoxic doses of vigabatrin into STN is an effective means of increasing local GABA concentrations and seizure threshold." | 1.43 | Continuous bilateral infusion of vigabatrin into the subthalamic nucleus: Effects on seizure threshold and GABA metabolism in two rat models. ( Gernert, M; Gey, L; Löscher, W, 2016) |
| "In all animals, hypsarrhythmia was abolished by the last treatment day." | 1.42 | Vigabatrin therapy implicates neocortical high frequency oscillations in an animal model of infantile spasms. ( Ballester-Rosado, C; Frost, JD; Hrachovy, RA; Le, JT; Lee, CL; Swann, JW, 2015) |
| "Limbic (psychomotor) seizure activity was evoked in albino Swiss mice by a current (32mA, 6Hz, 3s stimulus duration) delivered via ocular electrodes; type II isobolographic analysis was used to characterize the consequent anticonvulsant interactions between the various drug combinations for fixed-ratios of 1:1, 1:2, 1:5 and 1:10." | 1.40 | Interactions of levetiracetam with carbamazepine, phenytoin, topiramate and vigabatrin in the mouse 6Hz psychomotor seizure model - a type II isobolographic analysis. ( Florek-Luszczki, M; Luszczki, JJ; Wlaz, A, 2014) |
| "Tinnitus and hyperacusis, commonly seen in adults, are also reported in children." | 1.40 | Loudness perception affected by early age hearing loss. ( Fu, Q; Kumaraguru, A; Li, J; Manohar, S; Sun, W; Zhang, C, 2014) |
| " Similarly, we showed that RGC degeneration can be induced by pharmacologically blocking the taurine-transporter with the chronic administration of a selective inhibitor, which results in a decrease in the taurine levels both in the plasma and in the retinal tissue." | 1.39 | Taurine is a crucial factor to preserve retinal ganglion cell survival. ( Cadetti, L; Degardin, J; Dubus, E; Forster, V; Froger, N; Gaucher, D; Ivkovic, I; Jammoul, F; Lorach, H; Pain, D; Picaud, S; Sahel, JA; Simonutti, M, 2013) |
| "Tonic hind limb extension (seizure activity) was evoked in adult male albino Swiss mice by a current (sine-wave, 25 mA, 500 V, 50 Hz, 0." | 1.38 | Interactions of pregabalin with gabapentin, levetiracetam, tiagabine and vigabatrin in the mouse maximal electroshock-induced seizure model: a type II isobolographic analysis. ( Filip, D; Florek-Luszczki, M; Luszczki, JJ, 2012) |
| "Vigabatrin is a rationally developed antiepileptic drug, which acts by increasing GABA levels in the brain by irreversibly inhibiting GABA degradation." | 1.38 | Vigabatrin for focal drug delivery in epilepsy: bilateral microinfusion into the subthalamic nucleus is more effective than intranigral or systemic administration in a rat seizure model. ( Backofen-Wehrhahn, B; Bankstahl, M; Bröer, S; Gernert, M; Gey, L; Löscher, W, 2012) |
| "However, it is unclear whether the conductive hearing loss caused by otitis media in early age will affect sound tolerance later in life." | 1.37 | Early age conductive hearing loss causes audiogenic seizure and hyperacusis behavior. ( Allman, B; Fu, Q; Jayaram, A; Kumaraguru, A; Li, J; Manohar, S; Sun, W, 2011) |
| "Other epilepsies or autism often ensue especially in symptomatic IS (SIS)." | 1.36 | A model of symptomatic infantile spasms syndrome. ( Betancourth, D; Chudomelova, L; Galanopoulou, AS; Moshé, SL; Raffo, E; Scantlebury, MH, 2010) |
| "Clonic seizures were rare in NMDA-treated P25 rats, but valproate pretreatment increased their incidence significantly." | 1.36 | Vigabatrin but not valproate prevents development of age-specific flexion seizures induced by N-methyl-D-aspartate (NMDA) in immature rats. ( Kubová, H; Mares, P, 2010) |
| "Infantile spasms is a catastrophic childhood seizure disorder for which few animal models exist." | 1.35 | Infantile spasms and Down syndrome: a new animal model. ( Aleem, IS; Ashraf, A; Cortez, MA; Kanawaty, A; Liu, CC; Sadeghnia, HR; Shen, L; Snead, OC; Stewart, L; Trepanier, CH; Wu, Y, 2009) |
| "1995)." | 1.34 | Vigabatrin, a GABA transaminase inhibitor, reversibly eliminates tinnitus in an animal model. ( Bauer, CA; Brozoski, TJ; Spires, TJ, 2007) |
| "Vigabatrin was used with the aim of enhancing GABAergic neurotransmission, and in this way to investigate the role of this process in the properties of SWDs." | 1.34 | GABAergic mechanisms in absence epilepsy: a computational model of absence epilepsy simulating spike and wave discharges after vigabatrin in WAG/Rij rats. ( Bouwman, BM; Lopes da Silva, FH; Maris, E; Suffczynski, P; van Rijn, CM, 2007) |
| " These results present a novel interpretation of synergistic inhibition of certain epileptic discharges using vigabatrin and another drug, and that for successful synergistic treatment of epilepsies carefully designed timed dosage regimens are essential." | 1.33 | Antiepileptic action induced by a combination of vigabatrin and tiagabine. ( Fueta, Y; Kunugita, N; Schwarz, W, 2005) |
| "Vigabatrin was anticonvulsant in all groups for up to 13 days with a maximal effect 24 h after injection." | 1.32 | The central piriform cortex: anatomical connections and anticonvulsant effect of GABA elevation in the kindling model. ( Ebert, U; Löscher, W; Schwabe, K, 2004) |
| "Lamotrigine was the only drug which antagonized tonic convulsions in the MES test (ED50 = 36 mumol/kg)." | 1.30 | Comparison of the preclinical anticonvulsant profiles of tiagabine, lamotrigine, gabapentin and vigabatrin. ( Dalby, NO; Nielsen, EB, 1997) |
| "Vigabatrin was without effect on either pentylenetetrazol- or maximal electroshock-induced seizures, whereas tiagabine increased the latency to pentylenetetrazol seizures and reduced the incidence of maximal electroshock seizures." | 1.30 | Vigabatrin and tiagabine are pharmacologically different drugs. A pre-clinical study. ( Brodie, MJ; Butler, E; Sills, GJ; Thompson, GG, 1999) |
| "Treatment of phenytoin responders and nonresponders with other primary antiepileptic drugs showed that valproate and phenobarbital induced much smaller increases in focal seizure threshold in phenytoin nonresponders than in responders, whereas carbamazepine induced about the same threshold increase in both groups." | 1.29 | Pharmacological characterization of phenytoin-resistant amygdala-kindled rats, a new model of drug-resistant partial epilepsy. ( Hönack, D; Löscher, W; Rundfeldt, C, 1993) |
| "Kainic acid (KA)-induced convulsions are accompanied by histopathological changes that are most prominent in the temporal lobe structures." | 1.29 | Alpha 2-adrenoceptor agonist, dexmedetomidine, protects against kainic acid-induced convulsions and neuronal damage. ( Halonen, T; Kotti, T; Miettinen, R; Riekkinen, PJ; Toppinen, A; Tuunanen, J, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 14 (20.29) | 18.2507 |
| 2000's | 25 (36.23) | 29.6817 |
| 2010's | 25 (36.23) | 24.3611 |
| 2020's | 5 (7.25) | 2.80 |
| Authors | Studies |
|---|---|
| Solinski, HJ | 1 |
| Dranchak, P | 1 |
| Oliphant, E | 1 |
| Gu, X | 1 |
| Earnest, TW | 1 |
| Braisted, J | 1 |
| Inglese, J | 1 |
| Hoon, MA | 1 |
| Abrams, RPM | 1 |
| Yasgar, A | 1 |
| Teramoto, T | 1 |
| Lee, MH | 1 |
| Dorjsuren, D | 1 |
| Eastman, RT | 1 |
| Malik, N | 1 |
| Zakharov, AV | 1 |
| Li, W | 1 |
| Bachani, M | 1 |
| Brimacombe, K | 1 |
| Steiner, JP | 1 |
| Hall, MD | 1 |
| Balasubramanian, A | 1 |
| Jadhav, A | 1 |
| Padmanabhan, R | 1 |
| Simeonov, A | 1 |
| Nath, A | 1 |
| Shen, J | 1 |
| Wang, C | 1 |
| Ying, J | 1 |
| Xu, T | 1 |
| McAlinden, A | 1 |
| O'Keefe, RJ | 1 |
| Świąder, MJ | 1 |
| Świąder, K | 1 |
| Zakrocka, I | 1 |
| Krzyżanowski, M | 1 |
| Wróbel, A | 1 |
| Łuszczki, JJ | 1 |
| Czuczwar, SJ | 5 |
| Chern, CR | 1 |
| Chern, CJ | 1 |
| Velíšková, J | 2 |
| Velíšek, L | 2 |
| Fesli, R | 1 |
| Kuru Bektaşoğlu, P | 1 |
| Gürer, B | 1 |
| Arıkök, AT | 1 |
| Öztürk, ÖÇ | 1 |
| Bozkurt, H | 1 |
| Kertmen, H | 1 |
| Perescis, MFJ | 1 |
| van Luijtelaar, G | 1 |
| van Rijn, CM | 3 |
| Pawluski, JL | 1 |
| Kuchenbuch, M | 1 |
| Hadjadj, S | 1 |
| Dieuset, G | 1 |
| Costet, N | 1 |
| Vercueil, L | 1 |
| Biraben, A | 1 |
| Martin, B | 1 |
| Zhang, B | 1 |
| McDaniel, SS | 1 |
| Rensing, NR | 1 |
| Wong, M | 1 |
| Hall, AA | 1 |
| Young, C | 1 |
| Bodo, M | 1 |
| Mahon, RT | 1 |
| Florek-Luszczki, M | 2 |
| Wlaz, A | 1 |
| Luszczki, JJ | 6 |
| El Zahaf, NA | 1 |
| Salem Elhwuegi, A | 1 |
| Sun, W | 2 |
| Fu, Q | 2 |
| Zhang, C | 1 |
| Manohar, S | 2 |
| Kumaraguru, A | 2 |
| Li, J | 2 |
| Rasmussen, AD | 1 |
| Truchot, N | 1 |
| Pickersgill, N | 1 |
| Thale, ZI | 1 |
| Rosolen, SG | 1 |
| Botteron, C | 1 |
| Liu, XP | 1 |
| Chen, L | 1 |
| Zonouzi, M | 1 |
| Scafidi, J | 1 |
| Li, P | 1 |
| McEllin, B | 1 |
| Edwards, J | 1 |
| Dupree, JL | 1 |
| Harvey, L | 1 |
| Sun, D | 1 |
| Hübner, CA | 1 |
| Cull-Candy, SG | 1 |
| Farrant, M | 1 |
| Gallo, V | 1 |
| Frost, JD | 1 |
| Le, JT | 1 |
| Lee, CL | 1 |
| Ballester-Rosado, C | 1 |
| Hrachovy, RA | 1 |
| Swann, JW | 1 |
| Gey, L | 2 |
| Gernert, M | 2 |
| Löscher, W | 5 |
| Crabtree, GW | 1 |
| Park, AJ | 1 |
| Gordon, JA | 1 |
| Gogos, JA | 1 |
| Ratnaraj, N | 2 |
| Patsalos, PN | 2 |
| Dudra-Jastrzebska, M | 1 |
| Andres-Mach, MM | 1 |
| Sielski, M | 1 |
| Cortez, MA | 1 |
| Shen, L | 1 |
| Wu, Y | 1 |
| Aleem, IS | 1 |
| Trepanier, CH | 1 |
| Sadeghnia, HR | 1 |
| Ashraf, A | 1 |
| Kanawaty, A | 1 |
| Liu, CC | 1 |
| Stewart, L | 1 |
| Snead, OC | 1 |
| Jammoul, F | 2 |
| Wang, Q | 1 |
| Nabbout, R | 1 |
| Coriat, C | 1 |
| Duboc, A | 1 |
| Simonutti, M | 2 |
| Dubus, E | 2 |
| Craft, CM | 1 |
| Ye, W | 1 |
| Collins, SD | 1 |
| Dulac, O | 1 |
| Chiron, C | 1 |
| Sahel, JA | 2 |
| Picaud, S | 2 |
| Ferraro, G | 1 |
| Sardo, P | 1 |
| Kubová, H | 2 |
| Mares, P | 2 |
| Brady, KT | 1 |
| Scantlebury, MH | 2 |
| Galanopoulou, AS | 2 |
| Chudomelova, L | 2 |
| Raffo, E | 2 |
| Betancourth, D | 2 |
| Moshé, SL | 1 |
| Coppola, A | 1 |
| Russo, E | 1 |
| Citraro, R | 1 |
| Scicchitano, F | 1 |
| Urzino, A | 1 |
| Marra, R | 1 |
| Rispoli, V | 1 |
| De Sarro, G | 1 |
| Chachua, T | 1 |
| Yum, MS | 1 |
| Jayaram, A | 1 |
| Allman, B | 1 |
| Skirzewski, M | 1 |
| López, W | 1 |
| Mosquera, E | 1 |
| Betancourt, L | 1 |
| Catlow, B | 1 |
| Chiurillo, M | 1 |
| Loureiro, N | 1 |
| Hernández, L | 1 |
| Rada, P | 1 |
| Filip, D | 1 |
| Bröer, S | 1 |
| Backofen-Wehrhahn, B | 1 |
| Bankstahl, M | 1 |
| Nieoczym, D | 1 |
| Socała, K | 1 |
| Wlaź, P | 1 |
| Froger, N | 1 |
| Gaucher, D | 1 |
| Cadetti, L | 1 |
| Lorach, H | 1 |
| Degardin, J | 1 |
| Pain, D | 1 |
| Forster, V | 1 |
| Ivkovic, I | 1 |
| Raza, M | 1 |
| Al-Shabanah, OA | 1 |
| Lang, AP | 1 |
| de Angelis, L | 1 |
| Kang, TC | 2 |
| An, SJ | 1 |
| Park, SK | 1 |
| Hwang, IK | 1 |
| Won, MH | 2 |
| Gleich, O | 1 |
| Hamann, I | 1 |
| Klump, GM | 1 |
| Kittel, M | 1 |
| Strutz, J | 1 |
| Zhao, LX | 1 |
| Park, JG | 1 |
| Moon, YS | 1 |
| Basnet, A | 1 |
| Choi, J | 1 |
| Kim, EK | 1 |
| Jeong, TC | 1 |
| Jahng, Y | 1 |
| Lee, ES | 1 |
| Schwabe, K | 1 |
| Ebert, U | 1 |
| Fueta, Y | 1 |
| Kunugita, N | 1 |
| Schwarz, W | 1 |
| Madden, K | 1 |
| Clark, W | 1 |
| Lessov, N | 1 |
| Vinogradova, LV | 1 |
| Kuznetsova, GD | 1 |
| Shatskova, AB | 1 |
| Kjellström, U | 1 |
| Kjellström, S | 1 |
| Bruun, A | 1 |
| Andréasson, S | 1 |
| Ponjavic, V | 1 |
| Kim, DS | 1 |
| Kwak, SE | 1 |
| Kim, JE | 1 |
| Brozoski, TJ | 2 |
| Spires, TJ | 1 |
| Bauer, CA | 2 |
| Ciobanu, L | 1 |
| Bouwman, BM | 1 |
| Suffczynski, P | 1 |
| Lopes da Silva, FH | 1 |
| Maris, E | 1 |
| Wu, QE | 1 |
| Ban, TT | 1 |
| Yao, XM | 1 |
| Chang, XL | 1 |
| Wu, Q | 1 |
| Zhou, ZJ | 1 |
| André, V | 1 |
| Dubé, C | 1 |
| François, J | 1 |
| Leroy, C | 1 |
| Rigoulot, MA | 1 |
| Roch, C | 1 |
| Namer, IJ | 1 |
| Nehlig, A | 1 |
| Pitkänen, A | 1 |
| Halonen, T | 2 |
| Tsukamoto, K | 1 |
| Sved, AF | 1 |
| Rundfeldt, C | 2 |
| Hönack, D | 1 |
| Kotti, T | 1 |
| Tuunanen, J | 1 |
| Toppinen, A | 1 |
| Miettinen, R | 1 |
| Riekkinen, PJ | 1 |
| Ben-Menachem, E | 1 |
| Hosford, DA | 1 |
| Wang, Y | 1 |
| Dalby, NO | 1 |
| Nielsen, EB | 1 |
| Gibson, KM | 1 |
| Hoffmann, GF | 1 |
| Hodson, AK | 1 |
| Bottiglieri, T | 1 |
| Jakobs, C | 1 |
| Lücke, A | 1 |
| Musshoff, U | 1 |
| Köhling, R | 1 |
| Osterfeld, M | 1 |
| Mayer, T | 1 |
| Wolf, P | 1 |
| Schütte, W | 1 |
| Speckmann, EJ | 1 |
| Matagne, A | 1 |
| Klitgaard, H | 1 |
| White, HS | 1 |
| Sills, GJ | 1 |
| Butler, E | 1 |
| Thompson, GG | 1 |
| Brodie, MJ | 1 |
| Stromberg, MF | 1 |
| Mackler, SA | 1 |
| Volpicelli, JR | 1 |
| O'Brien, CP | 1 |
| Dewey, SL | 1 |
| Stuchlík, A | 1 |
| Liu, Z | 1 |
| Vergnes, M | 1 |
| Depaulis, A | 1 |
| Marescaux, C | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prednisolone vs. Vigabatrin in the First-line Treatment of Infantile Spasms[NCT02299115] | Phase 3 | 0 participants (Actual) | Interventional | 2017-09-05 | Withdrawn (stopped due to Most centres are now using oral steroids as 1st line treatment so question of efficacy is no longer of high interest.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for vigabatrin and Disease Models, Animal
| Article | Year |
|---|---|
Modeling new therapies for infantile spasms.
Topics: Adrenocorticotropic Hormone; Animals; Anticonvulsants; Disease Models, Animal; Humans; Infant; Mice; | 2010 |
Vigabatrin.
Topics: Animals; Anticonvulsants; Biological Availability; Child; Clinical Trials as Topic; Disease Models, | 1995 |
4-Hydroxybutyric acid and the clinical phenotype of succinic semialdehyde dehydrogenase deficiency, an inborn error of GABA metabolism.
Topics: Aldehyde Oxidoreductases; Animals; Anticonvulsants; Child; Developmental Disabilities; Disease Model | 1998 |
Comparative anticonvulsant and mechanistic profile of the established and newer antiepileptic drugs.
Topics: Animals; Anticonvulsants; Carbamazepine; Disease Models, Animal; Epilepsies, Partial; Felbamate; Fru | 1999 |
1 trial available for vigabatrin and Disease Models, Animal
| Article | Year |
|---|---|
Taurine deficiency is a cause of vigabatrin-induced retinal phototoxicity.
Topics: Amino Acids; Analysis of Variance; Animals; Child, Preschool; Disease Models, Animal; Dose-Response | 2009 |
64 other studies available for vigabatrin and Disease Models, Animal
| Article | Year |
|---|---|
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
Topics: Animals; Behavior, Animal; Cell-Free System; Dermatitis, Contact; Disease Models, Animal; Ganglia, S | 2019 |
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr | 2020 |
Inhibition of 4-aminobutyrate aminotransferase protects against injury-induced osteoarthritis in mice.
Topics: 4-Aminobutyrate Transaminase; Animals; Cartilage, Articular; Cells, Cultured; Chondrocytes; CpG Isla | 2019 |
Long-term vigabatrin treatment modifies pentylenetetrazole-induced seizures in mice: focused on GABA brain concentration.
Topics: 4-Aminobutyrate Transaminase; Animals; Anticonvulsants; Brain; Clonazepam; Disease Models, Animal; D | 2020 |
ACTON PROLONGATUM® suppresses spasms head to head with Acthar® Gel in the model of infantile spasms.
Topics: Adrenocorticotropic Hormone; Amino Acid Sequence; Animals; Animals, Newborn; Anticonvulsants; Diseas | 2020 |
Amelioration of Cerebral Vasospasm and Secondary Injury by Vigabatrin After Experimental Subarachnoid Hemorrhage in the Rabbit.
Topics: Animals; Anticonvulsants; Disease Models, Animal; Hippocampus; Neuroprotective Agents; Rabbits; Suba | 2020 |
Immediate versus late effects of vigabatrin on spike and wave discharges.
Topics: Animals; Disease Models, Animal; Electroencephalography; Epilepsy, Absence; Frontal Lobe; Male; Neur | 2020 |
Long-term negative impact of an inappropriate first antiepileptic medication on the efficacy of a second antiepileptic medication in mice.
Topics: Animals; Anticonvulsants; Disease Models, Animal; Drug Therapy, Combination; Electroencephalography; | 2018 |
Vigabatrin inhibits seizures and mTOR pathway activation in a mouse model of tuberous sclerosis complex.
Topics: Animals; Anticonvulsants; Astrocytes; Brain; Cell Proliferation; Cells, Cultured; Disease Models, An | 2013 |
Vigabatrin prevents seizure in swine subjected to hyperbaric hyperoxia.
Topics: Animals; Anticonvulsants; Decompression; Decompression Sickness; Disease Models, Animal; Diving; Hea | 2013 |
Interactions of levetiracetam with carbamazepine, phenytoin, topiramate and vigabatrin in the mouse 6Hz psychomotor seizure model - a type II isobolographic analysis.
Topics: Animals; Anticonvulsants; Avoidance Learning; Carbamazepine; Disease Models, Animal; Drug Combinatio | 2014 |
The effect of GABAmimetics on the duration of immobility in the forced swim test in albino mice.
Topics: Alprazolam; Animals; Depression; Diazepam; Disease Models, Animal; Dose-Response Relationship, Drug; | 2014 |
Loudness perception affected by early age hearing loss.
Topics: Acoustic Stimulation; Age Factors; Animals; Behavior, Animal; Conditioning, Operant; Disease Models, | 2014 |
The effects of taurine on vigabatrin, high light intensity and mydriasis induced retinal toxicity in the pigmented rat.
Topics: Animals; Anticonvulsants; Atropine; Disease Models, Animal; Electroretinography; Male; Mydriasis; My | 2015 |
Forward acoustic masking enhances the auditory brainstem response in a diotic, but not dichotic, paradigm in salicylate-induced tinnitus.
Topics: 4-Aminobutyrate Transaminase; Acoustic Stimulation; Animals; Audiometry; Auditory Pathways; Auditory | 2015 |
GABAergic regulation of cerebellar NG2 cell development is altered in perinatal white matter injury.
Topics: Action Potentials; Animals; Animals, Newborn; Asphyxia Neonatorum; Carbachol; Cell Count; Cells, Cul | 2015 |
Vigabatrin therapy implicates neocortical high frequency oscillations in an animal model of infantile spasms.
Topics: Animals; Anticonvulsants; Brain Mapping; Disease Models, Animal; Electroencephalography; Humans; Inf | 2015 |
Continuous bilateral infusion of vigabatrin into the subthalamic nucleus: Effects on seizure threshold and GABA metabolism in two rat models.
Topics: Animals; Basal Ganglia; Disease Models, Animal; Electric Stimulation; Female; gamma-Aminobutyric Aci | 2016 |
Cytosolic Accumulation of L-Proline Disrupts GABA-Ergic Transmission through GAD Blockade.
Topics: Animals; Central Nervous System; Cytosol; Disease Models, Animal; Gamma Rhythm; gamma-Aminobutyric A | 2016 |
Isobolographic and behavioral characterizations of interactions between vigabatrin and gabapentin in two experimental models of epilepsy.
Topics: Amines; Animals; Anticonvulsants; Behavior, Animal; Brain; Cyclohexanecarboxylic Acids; Disease Mode | 2008 |
Pharmacodynamic and pharmacokinetic interaction profiles of levetiracetam in combination with gabapentin, tiagabine and vigabatrin in the mouse pentylenetetrazole-induced seizure model: an isobolographic analysis.
Topics: Amines; Animals; Anticonvulsants; Brain; Cyclohexanecarboxylic Acids; Disease Models, Animal; Drug I | 2009 |
Infantile spasms and Down syndrome: a new animal model.
Topics: 4-Butyrolactone; Animals; Anticonvulsants; Baclofen; Brain; Disease Models, Animal; Down Syndrome; E | 2009 |
Cholecystokinin-8 sulfate modulates the anticonvulsant efficacy of vigabatrin in an experimental model of partial complex epilepsy in the rat.
Topics: Analysis of Variance; Animals; Anticonvulsants; Bicuculline; Convulsants; Dentate Gyrus; Disease Mod | 2009 |
Vigabatrin but not valproate prevents development of age-specific flexion seizures induced by N-methyl-D-aspartate (NMDA) in immature rats.
Topics: Age Factors; Animals; Animals, Newborn; Anticonvulsants; Behavior, Animal; Disease Models, Animal; E | 2010 |
Expanding treatment options for cocaine dependence.
Topics: Adult; Alcoholism; Animals; Cocaine-Related Disorders; Disease Models, Animal; Drug Approval; Drug-R | 2009 |
A model of symptomatic infantile spasms syndrome.
Topics: Adrenocorticotropic Hormone; Animals; Animals, Newborn; Antibiotics, Antineoplastic; Anticonvulsants | 2010 |
Vigabatrin has antiepileptogenic and antidepressant effects in an animal model of epilepsy and depression comorbidity.
Topics: Analysis of Variance; Animals; Anticonvulsants; Antidepressive Agents; Depression; Disease Models, A | 2011 |
Validation of the rat model of cryptogenic infantile spasms.
Topics: Adrenocorticotropic Hormone; Animals; Animals, Newborn; Betamethasone; Disease Models, Animal; Elect | 2011 |
Early age conductive hearing loss causes audiogenic seizure and hyperacusis behavior.
Topics: Acoustic Stimulation; Age Factors; Aging; Animals; Anticonvulsants; Auditory Perception; Behavior, A | 2011 |
Enhanced GABAergic tone in the ventral pallidum: memory of unpleasant experiences?
Topics: Animals; Behavior, Animal; Bicuculline; Depression; Disease Models, Animal; Enzyme Inhibitors; GABA- | 2011 |
Interactions of pregabalin with gabapentin, levetiracetam, tiagabine and vigabatrin in the mouse maximal electroshock-induced seizure model: a type II isobolographic analysis.
Topics: Amines; Animals; Anticonvulsants; Avoidance Learning; Confidence Intervals; Cyclohexanecarboxylic Ac | 2012 |
Vigabatrin for focal drug delivery in epilepsy: bilateral microinfusion into the subthalamic nucleus is more effective than intranigral or systemic administration in a rat seizure model.
Topics: Animals; Disease Models, Animal; Drug Delivery Systems; Epilepsy; Female; Microinjections; Rats; Rat | 2012 |
Sildenafil influences the anticonvulsant activity of vigabatrin and gabapentin in the timed pentylenetetrazole infusion test in mice.
Topics: Amines; Animals; Anticonvulsants; Avoidance Learning; Cyclohexanecarboxylic Acids; Disease Models, A | 2012 |
Taurine is a crucial factor to preserve retinal ganglion cell survival.
Topics: Animals; Cell Survival; Disease Models, Animal; Glaucoma; Membrane Glycoproteins; Membrane Transport | 2013 |
Effect of vigabatrin on contractile response to arachidonic acid and prostaglandins in smooth muscle preparations and platelet aggregation in experimental laboratory animals.
Topics: 4-Aminobutyrate Transaminase; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aorta; Arachidonic A | 2003 |
Experimental anxiety and antiepileptics: the effects of valproate and vigabatrin in the mirrored chamber test.
Topics: Animals; Anti-Anxiety Agents; Anticonvulsants; Anxiety; Conflict, Psychological; Disease Models, Ani | 2003 |
P2X2 and P2X4 receptor expression is regulated by a GABA(A) receptor-mediated mechanism in the gerbil hippocampus.
Topics: 3-Mercaptopropionic Acid; Animals; Disease Models, Animal; Enzyme Inhibitors; Epilepsy; GABA Agents; | 2003 |
Boosting GABA improves impaired auditory temporal resolution in the gerbil.
Topics: Acoustic Stimulation; Aging; Animals; Anticonvulsants; Auditory Pathways; Auditory Perceptual Disord | 2003 |
Design, synthesis and anticonvulsive activity of analogs of gamma-vinyl GABA.
Topics: Animals; Anticonvulsants; Disease Models, Animal; Drug Design; Isonipecotic Acids; Male; Mice; Nipec | 2004 |
The central piriform cortex: anatomical connections and anticonvulsant effect of GABA elevation in the kindling model.
Topics: Animals; Anticonvulsants; Disease Models, Animal; Epilepsy; Female; gamma-Aminobutyric Acid; Injecti | 2004 |
Antiepileptic action induced by a combination of vigabatrin and tiagabine.
Topics: Action Potentials; Animals; Anticonvulsants; Disease Models, Animal; Dose-Response Relationship, Dru | 2005 |
Failure of ischemic neuroprotection by potentiators of gamma-aminobutyric acid.
Topics: Animals; Anticonvulsants; Brain Ischemia; Disease Models, Animal; Fructose; gamma-Aminobutyric Acid; | 2003 |
Vigabatrin in low doses selectively suppresses the clonic component of audiogenically kindled seizures in rats.
Topics: Acoustic Stimulation; Animals; Anticonvulsants; Behavior, Animal; Disease Models, Animal; Dose-Respo | 2005 |
Retinal function in rabbits does not improve 4-5 months after terminating treatment with vigabatrin.
Topics: Administration, Oral; Animals; Anticonvulsants; Disease Models, Animal; Electroretinography; Follow- | 2006 |
The co-treatments of vigabatrin and P2X receptor antagonists protect ischemic neuronal cell death in the gerbil hippocampus.
Topics: Adenosine Triphosphatases; Animals; Cell Death; Disease Models, Animal; Drug Therapy, Combination; E | 2006 |
Isobolographic characterization of interactions between vigabatrin and tiagabine in two experimental models of epilepsy.
Topics: Animals; Anticonvulsants; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Interaction | 2007 |
Vigabatrin, a GABA transaminase inhibitor, reversibly eliminates tinnitus in an animal model.
Topics: 4-Aminobutyrate Transaminase; Adaptation, Physiological; Animals; Auditory Threshold; Behavior, Anim | 2007 |
Central neural activity in rats with tinnitus evaluated with manganese-enhanced magnetic resonance imaging (MEMRI).
Topics: Animals; Auditory Pathways; Auditory Perception; Auditory Threshold; Behavior, Animal; Brain Stem; C | 2007 |
GABAergic mechanisms in absence epilepsy: a computational model of absence epilepsy simulating spike and wave discharges after vigabatrin in WAG/Rij rats.
Topics: Action Potentials; Animals; Animals, Genetically Modified; Anticonvulsants; Brain; Computer Simulati | 2007 |
[Protective effects of vigabatrin and atropine against dimethoate induced-intoxication in mice].
Topics: Acute Disease; Animals; Atropine; Dimethoate; Disease Models, Animal; Insecticides; Male; Mice; Viga | 2007 |
Pathogenesis and pharmacology of epilepsy in the lithium-pilocarpine model.
Topics: Animals; Animals, Newborn; Anticonvulsants; Autoradiography; Cell Count; Cerebral Cortex; Deoxygluco | 2007 |
Prevention of neuronal cell death by anticonvulsants in experimental epilepsy (extended abstract).
Topics: Amygdala; Animals; Anticonvulsants; Brain; Carbamazepine; Cell Survival; Disease Models, Animal; gam | 1995 |
Enhanced gamma-aminobutyric acid-mediated responses in nucleus tractus solitarius of hypertensive rats.
Topics: 4-Aminobutyrate Transaminase; Aminocaproates; Analysis of Variance; Animals; Blood Pressure; Desoxyc | 1993 |
Pharmacological characterization of phenytoin-resistant amygdala-kindled rats, a new model of drug-resistant partial epilepsy.
Topics: Amino Acids; Aminocaproates; Amygdala; Animals; Anticonvulsants; Carbamazepine; Disease Models, Anim | 1993 |
Alpha 2-adrenoceptor agonist, dexmedetomidine, protects against kainic acid-induced convulsions and neuronal damage.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Anticonvulsants; Disease Models, A | 1995 |
Utility of the lethargic (lh/lh) mouse model of absence seizures in predicting the effects of lamotrigine, vigabatrin, tiagabine, gabapentin, and topiramate against human absence seizures.
Topics: Acetates; Amines; Animals; Anticonvulsants; Cyclohexanecarboxylic Acids; Disease Models, Animal; Dru | 1997 |
Comparison of the preclinical anticonvulsant profiles of tiagabine, lamotrigine, gabapentin and vigabatrin.
Topics: Acetates; Amines; Animals; Anticonvulsants; Cyclohexanecarboxylic Acids; Disease Models, Animal; Dos | 1997 |
Gabapentin potentiation of the antiepileptic efficacy of vigabatrin in an in vitro model of epilepsy.
Topics: 4-Aminobutyrate Transaminase; Acetates; Amines; Animals; Anticonvulsants; Bicuculline; Cyclohexaneca | 1998 |
Validation of corneally kindled mice: a sensitive screening model for partial epilepsy in man.
Topics: Amygdala; Animals; Anticonvulsants; Carbamazepine; Cornea; Disease Models, Animal; Dizocilpine Malea | 1998 |
Vigabatrin and tiagabine are pharmacologically different drugs. A pre-clinical study.
Topics: Animals; Anticonvulsants; Disease Models, Animal; Epilepsy; Evaluation Studies as Topic; Male; Mice; | 1999 |
The effect of gamma-vinyl-GABA on the consumption of concurrently available oral cocaine and ethanol in the rat.
Topics: Alcohol Drinking; Animals; Behavior, Addictive; Cocaine; Cocaine-Related Disorders; Disease Models, | 2001 |
Single systemic dose of vigabatrin induces early proconvulsant and later anticonvulsant effect in rats.
Topics: Action Potentials; Animals; Anticonvulsants; Disease Models, Animal; Dose-Response Relationship, Dru | 2001 |
Development of tolerance to the anticonvulsant effect of vigabatrin in amygdala-kindled rats.
Topics: Amino Acids; Aminocaproates; Amygdala; Animals; Anticonvulsants; Disease Models, Animal; Drug Admini | 1992 |
Evidence for a critical role of GABAergic transmission within the thalamus in the genesis and control of absence seizures in the rat.
Topics: Aminocaproates; Animals; Anticonvulsants; Disease Models, Animal; Electroencephalography; Epilepsy, | 1991 |